Management of Low MCH and MCHC with Normal Iron Panel

Understanding the Significance of Low MCH and MCHC

MCH (Mean Corpuscular Hemoglobin) is a measurement of the average amount of hemoglobin in a red blood cell, with low values indicating hypochromia 1
MCHC (Mean Corpuscular Hemoglobin Concentration) represents the average concentration of hemoglobin in a given volume of red blood cells 1
MCH is considered a more reliable marker of iron deficiency than MCV (Mean Corpuscular Volume) as it is less dependent on storage and counting machine used 1
Low MCH and MCHC are often early indicators of iron deficiency, even before anemia develops or when iron studies appear normal 1, 2

Early iron deficiency not yet reflected in iron studies can cause low MCH and MCHC 1
Functional iron deficiency (adequate stores but impaired utilization) can also lead to low MCH and MCHC 1
Thalassemia trait or other hemoglobinopathies should be considered as possible causes of low MCH and MCHC 1, 3
Reviewing complete blood count for other abnormalities, particularly hemoglobin level and MCV, is essential for further evaluation 2, 4
Assessing for symptoms of iron deficiency (fatigue, reduced exercise tolerance) is crucial 5

A therapeutic trial of oral iron supplementation is recommended for patients with slightly low MCH and MCHC values but normal iron panel 5
The American Gastroenterological Association recommends a trial of oral iron supplementation (ferrous sulfate 200 mg three times daily or equivalent) for 2-4 weeks 5
Monitoring response with repeat CBC after 2 weeks is necessary 1, 5
If there is a good response to iron (Hb rise ≥10 g/L within 2 weeks), continue iron therapy for 3 months to replenish stores 5

Monitoring hemoglobin, MCH, and MCHC after 2-4 weeks of iron therapy is essential 1, 5
If values normalize with iron therapy, continue treatment for 3 months total 5
After correction, monitoring CBC at 3-month intervals for one year, then after another year, is recommended 5

Normal iron studies do not exclude iron deficiency, especially in the presence of inflammation 1, 2
Avoiding iron supplementation in patients with confirmed hemochromatosis is crucial 7
Dietary modifications alone are insufficient for treating iron deficiency 7

For menstruating women, considering higher iron doses and longer duration of therapy is necessary 5
In patients with chronic kidney disease, evaluating for erythropoietin deficiency is essential 8, 9
For patients with inflammatory bowel disease, parenteral iron may be preferred over oral supplementation 6